10x Genomics, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Recent Updates
Recent Updates
Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025.
Began global commercial shipments of Atera, with extraordinary early demand translating into ambitious new research programs spanning discovery, translational and biopharma research.
Introduced Sentira, a cloud analysis platform to help customers turn complex biological datasets into insights, powered by NVIDIA accelerated computing for spatial data processing and Anthropic’s Claude for agentic AI analysis of single cell data.
“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.